- Home
- PGZ vs MGX Comparison
PGZ vs MGX Comparison
Compare PGZ & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- MGX
- Stock Information
- Founded
- PGZ 2012
- MGX 2018
- Country
- PGZ United States
- MGX United States
- Employees
- PGZ N/A
- MGX N/A
- Industry
- PGZ Investment Managers
- MGX
- Sector
- PGZ Finance
- MGX
- Exchange
- PGZ Nasdaq
- MGX NYSE
- Market Cap
- PGZ 70.2M
- MGX 62.1M
- IPO Year
- PGZ N/A
- MGX 2024
- Fundamental
- Price
- PGZ $10.46
- MGX $2.17
- Analyst Decision
- PGZ
- MGX Strong Buy
- Analyst Count
- PGZ 0
- MGX 4
- Target Price
- PGZ N/A
- MGX $13.00
- AVG Volume (30 Days)
- PGZ 23.0K
- MGX 904.3K
- Earning Date
- PGZ 01-01-0001
- MGX 08-13-2025
- Dividend Yield
- PGZ 12.26%
- MGX N/A
- EPS Growth
- PGZ N/A
- MGX N/A
- EPS
- PGZ N/A
- MGX N/A
- Revenue
- PGZ N/A
- MGX $45,263,000.00
- Revenue This Year
- PGZ N/A
- MGX N/A
- Revenue Next Year
- PGZ N/A
- MGX $11.75
- P/E Ratio
- PGZ N/A
- MGX N/A
- Revenue Growth
- PGZ N/A
- MGX N/A
- 52 Week Low
- PGZ $8.46
- MGX $1.23
- 52 Week High
- PGZ $10.59
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- PGZ 50.65
- MGX 71.83
- Support Level
- PGZ $10.43
- MGX $1.45
- Resistance Level
- PGZ $10.54
- MGX $2.47
- Average True Range (ATR)
- PGZ 0.07
- MGX 0.16
- MACD
- PGZ -0.01
- MGX 0.09
- Stochastic Oscillator
- PGZ 38.44
- MGX 75.47
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.